{"created":"2023-05-15T14:47:18.131489+00:00","id":64865,"links":{},"metadata":{"_buckets":{"deposit":"0403ee6a-2ad6-4c30-972b-ec66015c2a18"},"_deposit":{"created_by":1,"id":"64865","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"64865"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00064865","sets":["10:29"]},"author_link":["639230","639231","639232","639233"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2012-12-01","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"The first-line treatment for bone and soft-tissue tumors is inevitably surgery. Not all cases, however, are resectable, depending on the tumor location, size, and depth of invasion. Tumors of the extremities are often totally curative, whereas tumors involving spine, pelvis, and other axial part of the body may not allow resection at all in advanced cases. Some patients undergoing surgical resection may run the risk of being deprived of excretory function or suffering a major loss of ambulatory. Unresectable tumors were treated with external radiation therapy or brachytherapy combined with chemotherapy until recently. Yet, chemotherapy was not always effective for the treatment of a wide variety of sarcomas, and conventional radiotherapy achieved good results only for a few types of sarcomas. Thus, unresectable sarcomas had a very poor prognosis. \n Heavy charged particles (e.g., carbon ion) have higher biological effectiveness and more favorable dose distribution profiles than ordinary radiation beams (x-ray). Use of these particles provides the target tumor site with a large amount of irradiated doses possessing a high tumoricidal effect. We can declare that the carbon ion radiotherapy has dramatically changed the treatment strategies for unresectable bone and soft tissue tumors. Additional advantage for the carbon ion radiotherapy is that it hardly causes the patient discomfort or pain during irradiated time. The standard protocol for the treatment of bone and soft tissue tumors with the carbon ion radiotherapy consists of 12 to 16 irradiation sessions delivered over three to four weeks, once daily four times per week. The patient will lie in either supine or prone position on the table for 20 to 30 minutes. The irradiation of carbon ion beams will last for a few minutes.            \n  We started in June 1996 the clinical study of evaluate the safety and efficacy of carbon ion radiotherapy for unresectable bone and soft tissue sarcomas. The Ministry of Health, Labor and Welfare has approved the treatment method under the Advanced Medical Technology program since October 2003. A total of 854 patients were enrolled to the treatment protocols for unresectable bone and soft tissue sarcomas from 1996 to July 2012.Among sarcomas treated with carbon ion radiotherapy at our hospital, sacral chordomas accounted for the largest proportion. Sacral chordoma is a rare tumor, probably occurring in 20 to 30 patients among the entire Japanese population each year. We treated 22 patients in fiscal year 2009, which would comprise a large majority of the Japanese sacral chordoma patient population. We enrolled 185 patients with sacral chordoma until February, 2012. The 5-year local control and overall survival rates were 78% and 85%, respectively. Regarding the post-treatment salvage rates patients that were followed up for 5 or more years, no patient underwent colostomy by the time of the last observation due to the adverse reaction of carbon ion radiotherapy. Ninety five percent of the patients retained their own walking ability. To date, almost 200 patients with sacral chordoma have been treated at our facility. It will be the world's record for the largest number of treated cases of sacral chordomas in the single institution. Osteosaromas of the trunk constitute the next largest group. Patients with the tumors were not indicated for surgery, because of the tumor site or size, old age, and concurrent chronic illness. The 5-year overall survival rate was 35% in 91 patients with unresectable axial osteosarcoma. There were few reports regarding successful survival rate of patients with unresectable osteosarcoma.\n Over 15 years have passed since the start of the carbon ion radiotherapy for bone and soft-tissue tumors at our hospital. As mentioned above, the numbers of patients with these tumors treated at our hospital have been rising steadily each year. In particular, the last five years have witnessed a rapid increase, which reflects the growing popularity and potential needs among not only health-care providers but also patients. In order to meet the expanding medical demands, we will need to accumulate more evidence to broaden the indications for this novel technique. Heavy charged particle therapy could be an alternative to surgery that can be applied to patients with unresectable tumors, elderly patients with impaired health status, and those that are anticipated to experience permanent surgery-induced severe physical disabilities.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"2012 Catholic International Musculoskeletal Oncology Symposium","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Imai, Reiko"}],"nameIdentifiers":[{"nameIdentifier":"639230","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kamada, Tadashi"}],"nameIdentifiers":[{"nameIdentifier":"639231","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"今井 礼子","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"639232","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"鎌田 正","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"639233","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"Carbon Ion Radiotherapy for Patients with Bone and Soft-tissue Tumors","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Carbon Ion Radiotherapy for Patients with Bone and Soft-tissue Tumors"}]},"item_type_id":"10005","owner":"1","path":["29"],"pubdate":{"attribute_name":"公開日","attribute_value":"2012-12-06"},"publish_date":"2012-12-06","publish_status":"0","recid":"64865","relation_version_is_last":true,"title":["Carbon Ion Radiotherapy for Patients with Bone and Soft-tissue Tumors"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T21:06:43.234788+00:00"}